Progenitor Cell Screening for Regenerative Drug Discovery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for discovering regenerative drugs using stem cells are suboptimal due to the use of physiologically irrelevant targets, upstream cell types, difficulty in obtaining sufficient quantities of relevant progenitor cells, and variability in response to drugs, leading to inefficient identification of modulators for cell differentiation.
Innovation Solution
A method involving the isolation and use of physiologically relevant progenitor cells by arresting stem cells at specific differentiation stages, allowing for the identification of modulators that promote or inhibit cell signaling pathways, using sequential exposure to reaction conditions and culture media modifications to stall differentiation at relevant progenitor stages, facilitating high-throughput screening.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If self-renewing undifferentiated stem cells or cell lines are used in drug discovery screens, then sufficient quantities of cells can be easily obtained for screening, but the cell types are physiologically irrelevant and do not accurately reflect in vivo targets
Solution Approach 1:
The patent applies preliminary action by pre-differentiating stem cells into progenitor cells before conducting drug discovery screens. This involves exposing stem cells to specific culture conditions and differentiation factors in advance to generate physiologically relevant progenitor cell populations that retain self-renewal capacity while expressing tissue-specific markers, thereby ensuring both sufficient cell quantities and physiological relevance for subsequent screening
Solution Approach 2:
The patent uses progenitor cells as an intermediary between undifferentiated stem cells and fully differentiated cells. These intermediate cells serve as physiologically relevant targets that maintain proliferative capacity while expressing tissue-specific characteristics, bridging the gap between the ease of culturing undifferentiated cells and the physiological relevance of differentiated cells for drug discovery
2Productivity
If upstream stem cells are used as targets, then cell amplification is easy, but the cell types lie too far upstream in the developmental pathway to undergo directed differentiation in response to single agent application
Solution Approach 1:
The patent applies preliminary action by pre-differentiating stem cells into progenitor cells before conducting drug discovery screens. This involves exposing stem cells to specific culture conditions and differentiation factors in advance to generate physiologically relevant progenitor cell populations that retain self-renewal capacity while expressing tissue-specific markers, thereby ensuring both sufficient cell quantities and physiological relevance for subsequent screening
Solution Approach 2:
The patent employs parameter changes by systematically varying culture conditions, differentiation factors, and exposure times to generate progenitor cells at optimal stages of differentiation. By adjusting these parameters, the method achieves the right balance between maintaining cell proliferative capacity and inducing sufficient lineage commitment to respond to single-agent differentiation induction in drug screens
3Reliability
If primary adult stem cells are used, then physiologically relevant targets are obtained, but the cells are difficult to obtain in sufficient quantities and exhibit highly variable effects in response to drugs
Solution Approach 1:
The patent applies universality by using progenitor cells derived from various stem cell sources (embryonic, adult, induced pluripotent) that all share common characteristics of being physiologically relevant yet capable of amplification. This multi-functional approach allows the same screening methodology to be applied across different cell sources, ensuring both physiological relevance and sufficient cell quantities for high-throughput screening
4Manufacturing precision
If complex multi-step differentiation protocols are used, then specific cell lineages can be achieved, but the processes are time-consuming and difficult to optimize
Solution Approach 1:
The patent applies preliminary action by pre-differentiating stem cells into progenitor cells before conducting drug discovery screens. This involves exposing stem cells to specific culture conditions and differentiation factors in advance to generate physiologically relevant progenitor cell populations that retain self-renewal capacity while expressing tissue-specific markers, thereby ensuring both sufficient cell quantities and physiological relevance for subsequent screening
Solution Approach 2:
The patent employs parameter changes by systematically varying culture conditions, differentiation factors, and exposure times to generate progenitor cells at optimal stages of differentiation. By adjusting these parameters, the method achieves the right balance between maintaining cell proliferative capacity and inducing sufficient lineage commitment to respond to single-agent differentiation induction in drug screens
Data Source
AI summary
There is described a method for identifying a potential modulator of a cell signalling pathway, comprising the steps of: (a) providing a cell of a first cell type, wherein said first cell type may be differentiated to a second cell type via a progenitor cell by sequentially exposing said first cell type to two or more reaction conditions; (b) adding to or replacing at least one of said two or more reaction conditions to which the progenitor cell has been exposed with exposure to one or more different reaction conditions comprising said potential modulator; -and (c) monitoring the differentiation of the first cell type to determine formation of the second cell type.